Effects of incretins on blood pressure: A promising therapy for type 2 diabetes mellitus with hypertension

Effects of Incretin Hormones on β-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function

(2010) Sunder Mudaliar et al.   AMERICAN JOURNAL OF MEDICINE

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

(2010) Caroline M. Apovian et al.   AMERICAN JOURNAL OF MEDICINE

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

(2010) Que Liu et al.   Cardiovascular Diabetology

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

(2010) Anne Gill et al.   Cardiovascular Diabetology

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

(2010) M. Arakawa et al.   DIABETES

Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

(2010) E. S. Horton et al.   DIABETES CARE

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

(2010) J. B. Buse et al.   DIABETES CARE

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes

(2009) T. Okerson et al.   AMERICAN JOURNAL OF HYPERTENSION

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

(2009) Kunio Hirata et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

(2009) D. I. Brixner et al.   DIABETES OBESITY & METABOLISM

Diabetes medications and body weight

(2009) Joanna Mitri et al.   Expert Opinion On Drug Safety

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome

(2009) Kevin D. Laugero et al.   Metabolic Syndrome and Related Disorders

Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation

(2009) Kristopher C. Dozier et al.   PEPTIDES

Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo

(2009) David Nathanson et al.   REGULATORY PEPTIDES

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes

(2008) Antonio Cervera et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

(2008) Indu Poornima et al.   Circulation-Heart Failure

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

(2008) David C. Klonoff et al.   CURRENT MEDICAL RESEARCH AND OPINION

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE

The Potential Beneficial Role of Glucagon-like Peptide-1 in Endothelial Dysfunction and Heart Failure Associated with Insulin Resistance

(2008) T. Nyström   HORMONE AND METABOLIC RESEARCH

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

(2008) Goutam C. Mistry et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart

(2007) David P. Sonne et al.   REGULATORY PEPTIDES